以人工智能、新兴技术与异种移植重塑器官移植
器官移植是多种终末期器官衰竭的唯一根治手段,但供体短缺导致患者面临危及生命的等待。人工智能正用于指导器官分配、优化排斥监测与个体化免疫抑制方案;异种移植通过供体猪多基因编辑与改进的免疫抑制方案在减轻超急性排斥方面取得进展;再生医学(干细胞、三维类器官、三维生物打印)与生物材料、细胞封装有望创建患者特异性组织并实现局部免疫抑制。广泛临床 adoption 仍需严格验证、伦理框架与跨学科协作。
要点
- 人工智能整合临床、人口学与免疫学数据,辅助器官分配决策并优化排斥监测与免疫抑制方案。
- 异种移植通过供体猪多基因编辑与改进免疫抑制方案,在减轻肾、心、肝移植物超急性排斥方面取得进展。
- 再生医学与生物材料、细胞封装有望创建患者特异性组织并实现局部免疫抑制,但广泛临床应用仍需严格验证与伦理框架。
核心结论
- 结合人工智能引导的诊断、创新器官工程与先进免疫治疗,移植医学可朝着缓解器官短缺、优化患者结局并提升医疗体系效率的方向发展。
研究设计与样本
- 本文为综述,围绕人工智能、异种移植与再生医学在器官移植领域的应用与挑战进行汇总论述。
主要发现
- 人工智能工具通过整合临床、人口学与免疫学数据指导器官分配决策,并优化排斥监测、个体化免疫抑制方案及虚拟患者模拟。
- 异种移植通过供体猪多基因编辑与改进的免疫抑制方案,在减轻肾、心、肝移植物超急性排斥方面更接近实现。
- 再生医学方法包括干细胞治疗、三维类器官与三维生物打印,有望创建减少排斥并延长移植物存活的患者特异性组织。
- 生物材料与细胞封装可提供局部免疫抑制,有望简化移植后管理。
临床怎么用
- 原文未据此给出推荐。
局限性
- 广泛临床 adoption 需要严格验证、伦理框架与跨学科协作。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Organ transplantation remains the sole definitive treatment for many forms of end-stage organ failure, yet donor organ shortages impose life-threatening delays for thousands of patients worldwide. Mechanical supports and dialysis provide only temporary respite, while lifelong immunosuppression poses additional risks-including infections, malignancies and considerable healthcare costs. Recent innovations hold promise for overcoming these barriers. Artificial intelligence tools increasingly guide organ allocation decisions by integrating clinical, demographic and immunological data. They also refine rejection monitoring, personalize immunosuppressive regimens and facilitate virtual patient simulations. Meanwhile, xenotransplantation has progressed through multi-gene editing of donor pigs and improved immunosuppressive protocols, edging closer to mitigating hyperacute rejection in kidney, heart and liver grafts. In parallel, regenerative medicine approaches-spanning stem cell therapies, three-dimensional organoids and three-dimensional bioprinting-are poised to create patient-specific tissues that reduce rejection and enhance graft longevity. Biomaterials and cell encapsulation further offer localized immunosuppression, potentially streamlining post-transplant care. Yet widespread clinical adoption requires rigorous validation, ethical frameworks and interdisciplinary collaboration. By combining artificial intelligence-guided diagnostics, innovative organ engineering and advanced immunotherapies, transplant medicine can progress toward a future in which organ scarcity is alleviated, patient outcomes are optimized and healthcare systems operate with greater efficiency.
引用
- Loupy A, Preka E, Chen X, et al. Reshaping transplantation with AI, emerging technologies and xenotransplantation. Nat Med. 2025. PMID: 40659768. doi:10.1038/s41591-025-03801-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。